U.S. markets open in 2 hours 5 minutes
  • S&P Futures

    4,131.50
    +24.50 (+0.60%)
     
  • Dow Futures

    34,082.00
    +144.00 (+0.42%)
     
  • Nasdaq Futures

    13,231.25
    +131.00 (+1.00%)
     
  • Russell 2000 Futures

    2,185.00
    +16.40 (+0.76%)
     
  • Crude Oil

    64.68
    +0.86 (+1.35%)
     
  • Gold

    1,836.00
    +12.00 (+0.66%)
     
  • Silver

    27.36
    +0.31 (+1.13%)
     
  • EUR/USD

    1.2120
    +0.0035 (+0.29%)
     
  • 10-Yr Bond

    1.6680
    0.0000 (0.00%)
     
  • Vix

    21.54
    -6.05 (-21.93%)
     
  • GBP/USD

    1.4075
    +0.0023 (+0.16%)
     
  • USD/JPY

    109.3690
    -0.0650 (-0.06%)
     
  • BTC-USD

    50,753.64
    +1,430.98 (+2.90%)
     
  • CMC Crypto 200

    1,407.70
    +19.79 (+1.43%)
     
  • FTSE 100

    7,007.85
    +44.52 (+0.64%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Estimating The Intrinsic Value Of Core Laboratories N.V. (NYSE:CLB)

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of Core Laboratories N.V. (NYSE:CLB) by projecting its future cash flows and then discounting them to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. There's really not all that much to it, even though it might appear quite complex.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Check out our latest analysis for Core Laboratories

Is Core Laboratories fairly valued?

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$47.0m

US$64.6m

US$93.5m

US$119.5m

US$129.0m

US$136.1m

US$142.3m

US$147.6m

US$152.4m

US$156.8m

Growth Rate Estimate Source

Analyst x7

Analyst x7

Analyst x2

Analyst x2

Analyst x2

Est @ 5.54%

Est @ 4.49%

Est @ 3.75%

Est @ 3.24%

Est @ 2.88%

Present Value ($, Millions) Discounted @ 11%

US$42.3

US$52.3

US$68.2

US$78.4

US$76.2

US$72.4

US$68.1

US$63.6

US$59.1

US$54.7

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$635m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 11%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$157m× (1 + 2.0%) ÷ (11%– 2.0%) = US$1.8b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$1.8b÷ ( 1 + 11%)10= US$616m

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$1.3b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of US$30.7, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Core Laboratories as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 11%, which is based on a levered beta of 1.733. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Core Laboratories, we've put together three pertinent aspects you should assess:

  1. Risks: Take risks, for example - Core Laboratories has 4 warning signs (and 1 which is potentially serious) we think you should know about.

  2. Future Earnings: How does CLB's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.